GlassScriptPhysician profile
Rose Monardo
NPI 1407142250
$5,736.14
in general payments reported to CMS, 2019-2025
23 companies · $2,266 in 2025
The $2,266 reported for 2025 was more than what 90% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.71 · 2020: $39.61 · 2021: $77.08 · 2022: $186 · 2023: $1,057 · 2024: $2,039 · 2025: $2,266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,519 · Travel and Lodging: $1,792 · Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,519.27 |
| Travel and Lodging | $1,792.20 |
| Food and Beverage | $1,050.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,460.78 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $210.49 | 2022-2025 | |
| Hologic Sales and Service, LLC | $158.52 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Daiichi Sankyo INC. | $132.05 | 2019-2024 | Injectafer |
| Biogen, INC. | $127.39 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $70.45 | 2024 | Veozah |
| Organon LLC | $67.89 | 2024-2025 | Nexplanon, Nuvaring |
| Sumitomo Pharma America, INC. | $43.51 | 2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $43.32 | 2024-2025 | |
| Evofem Biosciences, INC. | $40.41 | 2022-2025 | Phexxi, Solosec, Phexx |
| Exeltis, USA INC. | $38.05 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $36.96 | 2023-2025 | |
| Pfizer INC. | $36.71 | 2022-2023 | |
| Minerva Surgical, INC | $36.20 | 2025 | |
| Exact Sciences Corporation | $33.12 | 2025 | The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $30.26 | 2019-2021 | |
| Covidien LP | $29.15 | 2019 | |
| Meditrina | $28.87 | 2024-2025 | |
| Agile Therapeutics, INC. | $24.76 | 2024 | Twirla |
| Therapeuticsmd, INC. | $23.65 | 2021 | |
| Avanos Medical | $23.01 | 2022 | |
| Olympus America INC. | $22.37 | 2020 | |
| Mylan Pharmaceuticals INC. | $18.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Monardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.